Search for dissertations about: "CYP2D6. debrisoquine"
Showing result 1 - 5 of 11 swedish dissertations containing the words CYP2D6. debrisoquine.
-
1. Pharmacogenetic analysis in sickness and in health - for better or for worse
Abstract : An individual's pharmacogenetic constitution may predict response to drugs, hormones and toxins, and might be a susceptibility factor for disease. Pharmacogenetic diversity is especially pronounced for drug metabolising enzymes. READ MORE
-
2. Pharmacokinetic consequences of CYP2D6 genotypes with emphasis on gene duplication / amplification
Abstract : The relationship between the major Caucasian and Oriental CYP2D6 genotypes and the disposition of two CYP2D6 substrates nortriptyline and debrisoquine was investigated. Caucasians with 0, 1, 2, 3/4 and 13 functional CYP2D6-genes as well as Chinese and Korean subjects homo- and heterozygous for the CYP2D6*1 and CYP2D6*10 alleles were included. READ MORE
-
3. Drug metabolic capacity in Koreans : CYP2D6 & CYP2C19 pheno- and genotype relationships in healthy volunteers and in patients
Abstract : This thesis aimed to investigate the relationship between pheno- and genotype of two drugmetabolizing enzymes CYP2D6 and CYYP2C19 in Koreans. Population studies were conducted in healthy volunteers to obtain basic information on these two enzymes. READ MORE
-
4. Enantioselective drug metabolism catalysed by the polymorphic CYP2D6 and CYP2C19 : a methodological investigation focused on mianserin, mephenytoin and omeprazole
Abstract : The aim of this thesis was to develop enantioselective analytical methods and apply them to studies of oxidative metabolism of chiral drugs catalysed by the polymorphic cytochrome P450 CYP2D6 and CYP2C 19 enzymes. The work has been focused on mianserin, mephenytoin and omeprazole. READ MORE
-
5. Consequences of CYP2D6 polymorphism for the disposition and dynamics of tolterodine : a novel drug in the treatment of urinary bladder overactivity
Abstract : The pharmacokinetics and pharmacological effects of tolterodine were studied in man following administration of increasing oral and intravenous single-doses. The influence of metabolic phenotype in extensive and poor metabolizers of debrisoquine was determined. READ MORE